News

Genomtec released its Q3 2021 report. Q3 was a period of intensified work on Genomtec®ID – the company obtained 2 additional patents (in ...

Genomtec started today the analysis to accelerate the planned commercialization of the Genomtec®ID platform. The analysis will include the ...

Genomtec today filed with the Polish Financial Supervision Authority (KNF) a prospectus prepared in connection with the planned transfer of the ...

Genomtec has received notification from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) ...

Company has has received a notice of allowance from the Japan Patent Office (JPO) granting the Company patent protection for the Genomtec®ID ...

Company has filed a patent application for a proprietary primer set, diagnostic method and reaction mixture composition for genetic diagnosis of ...